Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30;7(4):827-833.
doi: 10.1093/jalm/jfac003.

Clinical Performance of a Lateral Flow SARS-CoV-2 Total Antibody Assay

Affiliations

Clinical Performance of a Lateral Flow SARS-CoV-2 Total Antibody Assay

Beth L Cobb et al. J Appl Lab Med. .

Abstract

Background: Serological assays for SARS-CoV-2 are important tools for diagnosis in patients with negative RT-PCR testing, pediatric patients with multisystem inflammatory syndrome, and serosurveillance studies. However, lateral flow-based serological assays have previously demonstrated poor analytical and clinical performance, limiting their utility.

Methods: We assessed the ADEXUSDx COVID-19 lateral flow assay for agreement with diagnostic RT-PCR testing using 120 specimens from RT-PCR-positive patients, 77 specimens from symptomatic RT-PCR-negative patients, and 47 specimens obtained prepandemic. Specimens collected <14 days from symptom onset in RT-PCR-positive patients were compared relative to the Abbott SARS-CoV-2 IgG assay.

Results: The ADEXUSDx COVID-19 Test yielded an overall positive percent agreement (PPA) of 92.5% (95%CI 85.8 to 96.3) and negative percent agreement of 99.2% (95% CI 94.9-100.0) relative to RT-PCR and in prepandemic specimens. Relative to days from symptom onset, the PPA after 13 days was 100% (95% CI 94.2-100); from 7 to 13 days, 89.7 (95% CI 71.5-97.2); and from 0 to 7 days, 53.8 (95% CI 26.1-79.6). The overall agreement between the Abbott and ADEXUSDx assays was 80.9%. Twenty-five specimens were positive by both assays, 9 specimens were negative by both assays, and 8 specimens were positive by only the ADEXUSDx assay.

Conclusions: We demonstrate high PPA and negative percent agreement of the ADEXUSDx COVID-19 assay and diagnostic testing by RT-PCR, with PPA approximately 90% by 7 days following symptom onset. The use of waived testing for antibodies to SARS-CoV-2 with high sensitivity and specificity provide a further tool for combatting the COVID-19 pandemic.

Keywords: COVID-19; SARS-CoV-2; antibody; immunity; serology.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PPA of the ADEXUSDx assay and time from symptom onset. Specimens from patients with RT-PCR–confirmed SARS-CoV-2 infection were analyzed on the ADEXUSDX assay and plotted by time from symptom onset.
Fig. 2
Fig. 2
Agreement between the ADXUSDx and Abbott assay. Specimens from patients with <14 days of symptoms were tested using both assays. Shown are the results of each relative to the time from symptom onset. Black circles were positive and gray circles were negative for the ADEXUSDx assay. The dotted line indicates the positive cutoff by the Abbott assay.

References

    1. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Published April 11, 2020. Last updated January 18, 2022. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatmen... (Accessed January 2021).
    1. Infectious Diseases Society of America. IDSA guidelines on the diagnosis of COVID-19: serologic testing. Published August 18, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-serology (Accessed August 2021).
    1. Food and Drug Administration. In vitro diagnostics EUAs—serology and other adaptive immune response tests for SARS-CoV-2. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em... (Accessed August 2021).
    1. Clinical & Laboratory Standards Institute. Overcoming phlebotomy challenges in pediatric patients. Published July 15, 2020. https://clsi.org/about/blog/overcoming-phlebotomy-challenges-in-pediatri... (Accessed August 2021).
    1. Farnsworth CW, Anderson NW.. SARS-CoV-2 serology: much hype, little data. Clin Chem 2020;66:875–7. - PMC - PubMed

Substances

Supplementary concepts